Literature DB >> 15358653

Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum.

V A Semenova1, E Steward-Clark, K L Stamey, T H Taylor, D S Schmidt, S K Martin, N Marano, C P Quinn.   

Abstract

An anti-Anthrax Vaccine Adsorbed (anti-AVA) standard human reference serum pool, AVR414, has been prepared, and the total and protective antigen (PA)-specific immunoglobulin G (IgG) were quantified. AVR414 was prepared by plasmapheresis of healthy adults who had received a minimum of four subcutaneous injections of AVA. Mass values (in milligrams per milliliter) for total IgG and IgG subclasses 1 to 4 were determined by radial immunodiffusion. Anti-PA-specific IgG assignment (in micrograms per milliliter) was done by consensus of two complementary approaches: homologous enzyme-linked immunosorbent assay (ELISA) with affinity-purified anti-PA IgG as a calibrator and summation of mean PA-specific IgG subclass concentrations determined by IgG subclass-specific ELISA using the United States National Reference Preparation for Human Serum Proteins as a standard. The total IgG concentration assigned to AVR414 reference serum was 8.33 mg/ml. IgG subclass concentrations were the following: for IgG1, 4.48 mg/ml; for IgG2, 3.35 mg/ml; for IgG3, 0.37 mg/ml; and for IgG4, 0.30 mg/ml. The assigned mass value for total anti-PA-specific IgG was 141.2 microg/ml. Anti-PA-specific IgG subclass concentrations were the following: for IgG1, 79.6 microg/ml; for IgG2, 35.3 microg/ml; for IgG3, 3.2 microg/ml; and for IgG4, 25.3 microg/ml. Human reference serum pool AVR414 will have direct application in the standardization of anthrax serological assays, in reagent qualification, and as a standard for quantification of PA-specific IgG in humans who have been vaccinated with or otherwise exposed to Bacillus anthracis PA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358653      PMCID: PMC515271          DOI: 10.1128/CDLI.11.5.919-923.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  27 in total

1.  Effect of a new international reference preparation for proteins in human serum (certified reference material 470) on results of the College of American Pathologists Surveys for plasma proteins.

Authors:  A M Johnson; J T Whicher; T B Ledue; A Carlström; Y Itoh; P H Petersen
Journal:  Arch Pathol Lab Med       Date:  2000-10       Impact factor: 5.534

2.  Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans.

Authors:  Phillip R Pittman; Gina Kim-Ahn; Dominique Y Pifat; Kevin Coonan; Paul Gibbs; Steve Little; Judith G Pace-Templeton; Robert Myers; Gerald W Parker; Arthur M Friedlander
Journal:  Vaccine       Date:  2002-01-31       Impact factor: 3.641

3.  Optimized production and purification of Bacillus anthracis lethal factor.

Authors:  S Park; S H Leppla
Journal:  Protein Expr Purif       Date:  2000-04       Impact factor: 1.650

4.  Anthrax vaccine: short-term safety experience in humans.

Authors:  P R Pittman; P H Gibbs; T L Cannon; A M Friedlander
Journal:  Vaccine       Date:  2001-12-12       Impact factor: 3.641

Review 5.  Validation of serological assays for diagnosis of infectious diseases.

Authors:  R H Jacobson
Journal:  Rev Sci Tech       Date:  1998-08       Impact factor: 1.181

6.  Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.

Authors:  J A Jernigan; D S Stephens; D A Ashford; C Omenaca; M S Topiel; M Galbraith; M Tapper; T L Fisk; S Zaki; T Popovic; R F Meyer; C P Quinn; S A Harper; S K Fridkin; J J Sejvar; C W Shepard; M McConnell; J Guarner; W J Shieh; J M Malecki; J L Gerberding; J M Hughes; B A Perkins
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

7.  Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001.

Authors:  Puneet K Dewan; Alicia M Fry; Kayla Laserson; Bruce C Tierney; Conrad P Quinn; James A Hayslett; Laura N Broyles; Andi Shane; Kevin L Winthrop; Ivan Walks; Larry Siegel; Thomas Hales; Vera A Semenova; Sandra Romero-Steiner; Cheryl Elie; Rima Khabbaz; Ali S Khan; Rana A Hajjeh; Anne Schuchat
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

8.  Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response.

Authors:  Vincent P Hsu; Susan L Lukacs; Thomas Handzel; James Hayslett; Scott Harper; Thomas Hales; Vera A Semenova; Sandra Romero-Steiner; Cheryl Elie; Conrad P Quinn; Rima Khabbaz; Ali S Khan; Gregory Martin; John Eisold; Anne Schuchat; Rana A Hajjeh
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

9.  Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.

Authors:  Daniel B Jernigan; Pratima L Raghunathan; Beth P Bell; Ross Brechner; Eddy A Bresnitz; Jay C Butler; Marty Cetron; Mitch Cohen; Timothy Doyle; Marc Fischer; Carolyn Greene; Kevin S Griffith; Jeannette Guarner; James L Hadler; James A Hayslett; Richard Meyer; Lyle R Petersen; Michael Phillips; Robert Pinner; Tanja Popovic; Conrad P Quinn; Jennita Reefhuis; Dori Reissman; Nancy Rosenstein; Anne Schuchat; Wun-Ju Shieh; Larry Siegal; David L Swerdlow; Fred C Tenover; Marc Traeger; John W Ward; Isaac Weisfuse; Steven Wiersma; Kevin Yeskey; Sherif Zaki; David A Ashford; Bradley A Perkins; Steve Ostroff; James Hughes; David Fleming; Jeffrey P Koplan; Julie L Gerberding
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

10.  First case of bioterrorism-related inhalational anthrax in the United States, Palm Beach County, Florida, 2001.

Authors:  Marc S Traeger; Steven T Wiersma; Nancy E Rosenstein; Jean M Malecki; Colin W Shepard; Pratima L Raghunathan; Segaran P Pillai; Tanja Popovic; Conrad P Quinn; Richard F Meyer; Sharif R Zaki; Savita Kumar; Sherrie M Bruce; James J Sejvar; Peter M Dull; Bruce C Tierney; Joshua D Jones; Bradley A Perkins
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more
  24 in total

1.  Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Authors:  E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.

Authors:  Phillip R Pittman; Susan F Leitman; Julio G Barrera Oro; Sarah L Norris; Nina M Marano; Manmohan V Ranadive; Bonnie S Sink; Kelly T McKee
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

3.  Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization.

Authors:  Kenneth Smith; Sherry R Crowe; Lori Garman; Carla J Guthridge; Jennifer J Muther; Emily McKee; Nai-Ying Zheng; A Darise Farris; Joel M Guthridge; Patrick C Wilson; Judith A James
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

4.  A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.

Authors:  Conrad P Quinn; Carol L Sabourin; Nancy A Niemuth; Han Li; Vera A Semenova; Thomas L Rudge; Heather J Mayfield; Jarad Schiffer; Robert S Mittler; Chris C Ibegbu; Jens Wrammert; Rafi Ahmed; April M Brys; Robert E Hunt; Denyse Levesque; James E Estep; Roy E Barnewall; David M Robinson; Brian D Plikaytis; Nina Marano
Journal:  Clin Vaccine Immunol       Date:  2012-08-29

5.  Rapid, sensitive, and specific lateral-flow immunochromatographic device to measure anti-anthrax protective antigen immunoglobulin g in serum and whole blood.

Authors:  Raymond E Biagini; Deborah L Sammons; Jerome P Smith; Barbara A MacKenzie; Cynthia A F Striley; John E Snawder; Shirley A Robertson; Conrad P Quinn
Journal:  Clin Vaccine Immunol       Date:  2006-05

6.  Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.

Authors:  Kristin H Clement; Thomas L Rudge; Heather J Mayfield; Lena A Carlton; Arelis Hester; Nancy A Niemuth; Carol L Sabourin; April M Brys; Conrad P Quinn
Journal:  Clin Vaccine Immunol       Date:  2010-08-25

7.  Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge.

Authors:  Michael P Fay; Dean A Follmann; Freyja Lynn; Jarad M Schiffer; Gregory V Stark; Robert Kohberger; Conrad P Quinn; Edwin O Nuzum
Journal:  Sci Transl Med       Date:  2012-09-12       Impact factor: 17.956

8.  Towards a nanoparticle-based prophylactic for maternal autoantibody-related autism.

Authors:  Amir Bolandparvaz; Rian Harriman; Kenneth Alvarez; Kristina Lilova; Zexi Zang; Andy Lam; Elizabeth Edmiston; Alexandra Navrotsky; Natalia Vapniarsky; Judy Van De Water; Jamal S Lewis
Journal:  Nanomedicine       Date:  2019-07-23       Impact factor: 5.307

9.  Validation of high throughput screening of human sera for detection of anti-PA IgG by Enzyme-Linked Immunosorbent Assay (ELISA) as an emergency response to an anthrax incident.

Authors:  Vera A Semenova; Evelene Steward-Clark; Panagiotis Maniatis; Monica Epperson; Amit Sabnis; Jarad Schiffer
Journal:  Biologicals       Date:  2016-11-01       Impact factor: 1.856

10.  Domain specificity of the human antibody response to Bacillus anthracis protective antigen.

Authors:  Donald C Reason; Anuska Ullal; Justine Liberato; Jinying Sun; Wendy Keitel; Jianhui Zhou
Journal:  Vaccine       Date:  2008-06-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.